BioInfra Co., Ltd. (KOSDAQ:199730)
South Korea · Delayed Price · Currency is KRW 1,771.00
-23.00 (-1.28%)
At close: Aug 12, 2026
BioInfra Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 23,207 | 23,148 | 23,833 | 30,129 | 35,427 | 30,555 |
Revenue Growth | -4.31% | -2.88% | -20.89% | -14.96% | 15.95% | 55.82% |
Gross Profit Gross Profit Growth | 5,294 | 5,230 | 5,600 | 9,472 | 13,898 | 11,979 |
Operating Income Operating Income Growth | -6,479 | -6,277 | -5,117 | 1,305 | 6,360 | 7,463 |
Net Income Net Income Growth | -9,887 | -9,131 | -3,976 | 2,002 | 6,237 | 6,234 |
Earnings Per Share EPS Growth | -2031.96 | -1877.13 | -820.00 | 426.00 | 1511.00 | 1510.00 |
EPS Growth | - | - | - | -71.81% | 0.07% | -50.43% |
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Phase 1 Clinical Trial Phase 1 Clinical Trial Growth | 12,459 | - | - | - | - |
Bioequivalence Testing Bioequivalence Testing Growth | 9,765 | - | - | - | - |
Clinical / Non-clinical Sample Analysis Clinical / Non-clinical Sample Analysis Growth | 1,190 | - | - | - | - |
Sample Analysis for Not Licensing Purposes, etc. Sample Analysis for Not Licensing Purposes, etc. Growth | 325.77 | - | - | - | - |
Non-approved Clinical Trials Non-approved Clinical Trials Growth | 34.71 | - | - | - | - |
Clinical Trials for Approval Clinical Trials for Approval Growth | 22.01 | - | - | - | - |
Other Other Growth | 36.94 | - | - | - | - |
Clinical Trials and New Drug Specimen Analysis Clinical Trials and New Drug Specimen Analysis Growth | - | 30,129 | 35,427 | 30,555 | 19,535 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 8,283 | 8,172 | 11,060 | 14,705 | 7,539 | 6,183 |
Total Debt Total Debt Growth | 12,700 | 11,857 | 8,669 | 8,991 | 8,472 | 15,012 |
Net Cash (Debt) Net Cash Growth | -4,417 | -3,686 | 2,391 | 5,714 | -932.12 | -8,829 |
Net Cash Growth | - | - | -58.16% | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -907.81 | -757.69 | 493.03 | 1216.13 | -225.81 | -2138.51 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -808.74 | -1,501 | 1,729 | 679.3 | 8,425 | 6,563 |
Capital Expenditures CapEx Growth | -1,200 | -1,322 | -2,800 | -3,074 | -10,531 | -14,122 |
Free Cash Flow Free Cash Flow Growth | -2,009 | -2,824 | -1,071 | -2,395 | -2,107 | -7,559 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 22.81% | 22.59% | 23.50% | 31.44% | 39.23% | 39.20% |
Operating Margin | -27.92% | -27.12% | -21.47% | 4.33% | 17.95% | 24.42% |
Pretax Margin | -36.14% | -35.10% | -24.65% | 4.24% | 19.72% | 23.23% |
Profit Margin | -42.60% | -39.45% | -16.68% | 6.64% | 17.61% | 20.40% |
FCF Margin | -8.66% | -12.20% | -4.49% | -7.95% | -5.95% | -24.74% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 29.02 | - | - |
PS Ratio | 0.38 | 0.99 | 1.31 | 1.93 | - | - |